drugset / Trial / NCT02212769

the Pharmacokinetic Profiles of Losartan With DW1029M

NCT02212769

Phase 1 Completed 12 enrolled Dong Wha Pharmaceutical Co. Ltd.
RandomizedCrossoverOpen-labelHealth-services research

Summary

Phase I clinical study to evaluate DW1029M influence the pharmacokinetic profiles of Losartan after oral administration in healthy male volunteer

Timeline

Start
2014-08
Primary completion
2015-01
Completion
2015-02

Drugs

EvaluationDrugModalityDoseRoute
Subject DW1029M Unknown 1200 mg Oral
Subject Losartan Other / unclassified 50 mg Oral

Indications

No indication recorded.